Adults 18 to 85, female only, with Gut Health. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Stool Short-chain Fatty Acids Production Following Each Intervention Between Mothers and DaughtersPrimary· 14 days
Changes in stool short-chain fatty acids production from baseline after each intervention (cellulose control and dietary fibre supplement) between mothers and daughters
Group
Value
95% CI
Mothers Dietary Fibre Supplement
50
± 0.176
Mothers Cellulose Control
26
± 0.709
Daughters Dietary Fibre Supplement
41.7
± 0.106
Daughters Cellulose Control
47.8
± 0.126
Sponsor's own description
Dietary fibres are complex carbohydrates present in fruit, vegetables, grains, and beans which are broken down into smaller molecules (short-chain fatty acids) in the colon by the gut microbiota. Increased intake of dietary fibres is associated with a lower risk of type 2 diabetes, obesity, or heart disease. Despite their health benefits, most people consume half of the daily recommended intake (30 grams) of dietary fibres. This trend has become more apparent in the past few decades with the advent of ultra-processed foods which are poor in dietary fibres. Since this change in dietary habits is more recent, the research team hypothesizes that older generations have a more diverse and better adapted gut microbiota at breaking down dietary fibres compared to younger generations.
The aims of this study are to examine the effects of the daily intake over four weeks of a dietary fibres supplement on the gut microbiota, metabolic profiles, and general health in a transgenerational cohort (grandmother, mother and daughter OR mother and daughter) compared to cellulose control.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
NCT07421596 — An 8-Week Study Evaluating Gut and Digestive Health After Use of a Dietary Supplement System
· NA
· recruiting
NCT07423897 — Consumer Health Study Aims to Evaluate the Safety, Tolerability and Impact of ED02 Probiotic Supplement on Gastrointesti
· NA
· active not recruiting
NCT07408518 — Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes
· NA
· active not recruiting
NCT07371975 — A Study to Evaluate the Effects of a Butyrate-Polyphenol Formulation on Gut Health and Associated Symptoms
· NA
· recruiting
NCT07109713 — The Effect Cranberry-Based Products on the Female Microbiome
· NA
· recruiting
Other Imperial College London trials
Trials by the same sponsor.
NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH
· NA
· not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants
· Phase 1
· not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing
· NA
· not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy
· Phase 2
· not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study
· not yet recruiting
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 29 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05364437.